Interpretable Machine Learning Model for Individualized Survival Prediction of Multiple System Atrophy
Movement Disorders · 15.06.2026
DOI: 10.1002/mds.70404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 15.06.2026. Verfasst von Xiao Dong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, China. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Scientific Research Program of FuRong Laboratory.
Abstract (Originalsprache)
Background
Multiple system atrophy (MSA) is a fatal neurodegenerative disease with highly variable progression and poor prognosis. This study aimed to characterize survival patterns, identify prognostic factors, and develop an interpretable machine learning model for individualized survival prediction in MSA.
Methods
In this multicenter longitudinal cohort study, 391 MSA patients were analyzed. Prognostic factors were identified using Kaplan–Meier and Cox regression analyses. Six survival models were trained with five‐fold cross‐validation, with Shapley Additive Explanations (SHAP) being used for feature selection and interpretability.
Results
During a median follow‐up of 4.9 years, 149 deaths occurred, with a median survival of 6.9 years. The random survival forest model achieved the best performance (C‐index 0.769; mean time‐dependent area under the curve [AUC] 0.815) with 11 predictors. An interactive web‐based platform and a risk score were developed for clinical application.
Conclusion
This interpretable machine learning model accurately predicted individualized survival in MSA and identified key prognostic factors. © 2026 International Parkinson and Movement Disorder Society.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Central South University, Changsha, China.
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, China.
- National International Collaborative Research Center for Medical Metabolomics, Central South University, Changsha, China.
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China.
ORCID-Profile: Beisha Tang, Hong Jiang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Scientific Research Program of FuRong Laboratory
- Natural Science Foundation of Hunan Province
- Major Scientific Research Project for High-level Health Talent in Hunan Province
- AI Medical Device Innovation
- Central South University Research Programme of Advanced Interdisciplinary Study
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Dong, X., Chen, D., Wan, L., Chen, Z., Peng, L., Long, Z., Wu, J., Ouyang, R., Long, X., Du, K., Wu, X., Xiao, X., He, R., Zeng, D., Qiu, R., Tang, B., & Jiang, H. (2026). Interpretable Machine Learning Model for Individualized Survival Prediction of Multiple System Atrophy. Movement Disorders. https://doi.org/10.1002/mds.70404
Vancouver
Dong X, Chen D, Wan L, Chen Z, Peng L, Long Z, et al. Interpretable Machine Learning Model for Individualized Survival Prediction of Multiple System Atrophy. Movement Disorders. 2026. doi:10.1002/mds.70404
BibTeX
@article{Dong2026,
author = {Dong, Xiao and Chen, Daji and Wan, Linlin and Chen, Zhao and Peng, Linliu and Long, Zhe and Wu, Jinze and Ouyang, Riwei and Long, Xiafei and Du, Kefang and Wu, Xiaokang and Xiao, XinYing and He, Ruqing and Zeng, Daren and Qiu, Rong and Tang, Beisha and Jiang, Hong},
title = {Interpretable Machine Learning Model for Individualized Survival Prediction of Multiple System Atrophy},
journal = {Movement Disorders},
year = {2026},
doi = {10.1002/mds.70404}
}
EUVIMED